Mutares Stock Tumbles to Fresh Low Despite €105 Million Cash Injection

The disconnect between Mutares’ strategic ambitions and its stock market performance has rarely been starker. The Munich-based private equity firm just raised roughly €105 million through a capital increase, pricing new shares at €24.50 apiece, yet its equity continues to slide. On Friday, the stock touched €23.60, marking a fresh 52-week low and closing well below the placement price.

The capital raise added approximately 4.2 million new shares to the market, bringing the total voting rights to around 25.6 million. Management earmarked about four-fifths of the proceeds for expansion in the United States and further European acquisitions, with the remainder earmarked for balance sheet strengthening. But investors have so far greeted the move with skepticism — the stock has shed over a quarter of its value in the past month alone, and is down roughly 21% year-to-date. Over a 12-month horizon, the decline deepens to nearly 32%.

A Turnaround Play in Plastics

The centerpiece of Mutares’ growth strategy is the planned acquisition of SABIC’s plastics division, a business generating billions in revenue and employing nearly 3,000 people. The enterprise value for the transaction stands at $450 million, with completion expected in the second half of the year. This is a classic Mutares play — the division has been posting operating losses, and its European plants are running at just 50% capacity. Restructuring efforts are already underway, with the Spanish site in Cartagena under particular scrutiny.

Should investors sell immediately? Or is it worth buying Mutares?

Portfolio Reshuffling and a Delayed IPO

Alongside the transatlantic push, Mutares is recalibrating its existing portfolio. The planned initial public offering of its subsidiary Amaneos has been pushed back to 2027 or 2028. The company describes the unit as profitable, but apparently needs more time before making its stock market debut.

Analysts Hold Their Ground

Despite the persistent share price weakness, sell-side analysts remain firmly bullish. Warburg Research maintains a price target of €46 with a buy rating, while Jefferies sees the stock climbing to €37, also with a buy recommendation. Both firms expect Mutares to continue executing its restructuring playbook successfully and to generate value through profitable divestitures down the line.

Key Test Ahead

The market will get a clearer picture of the group’s financial health on Tuesday, April 28, when Mutares releases its audited annual results for fiscal 2025. Investors will be scrutinizing net income, the outlook for the current year, and any concrete details on how the SABIC integration is progressing. The capital raise has given management firepower — but the stock’s trajectory suggests the market is waiting for proof that the strategy will deliver.